Benzatropine
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Benzatropine
- Pharmacist Assessment Report
- Benzatropine: anticholinergic (muscarinic receptor antagonist) → PLA2G6-associated neurodegeneration
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Benzatropine: anticholinergic (muscarinic receptor antagonist) → PLA2G6-associated neurodegeneration
One-Sentence Summary
Benzatropine is an anticholinergic medicine used for parkinsonism and related movement disorders. The TxGNN model predicts it may be relevant to PLA2G6-associated neurodegeneration, but no clinical trials and no publications were found to support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | PLA2G6-associated neurodegeneration |
| TxGNN Prediction Score | 0.9917 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, benzatropine is an anticholinergic that blocks muscarinic acetylcholine receptors and is also described as inhibiting dopamine reuptake.
PLA2G6-associated neurodegeneration can include dystonia-parkinsonism features (for example, juvenile-onset parkinsonism). A plausible, but unverified, link is that an anticholinergic could offer symptomatic relief of these movement features. This would not be disease modification, because the underlying defect lies in phospholipase A2 group VI function and lipid metabolism. This link is a hypothesis only and has not been tested in the data compiled here.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11249C | Benzatropine Injection | Injection containing benzatropine mesilate 2 mg in 2 mL | Not recorded in the local data |
One licence is recorded and it is valid (single-ingredient product).
Safety Considerations
Specific warnings and contraindications from the approved label were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.
Drug Interactions: 78 interacting drugs were identified. Major-level interactions include:
- Potassium chloride
- Potassium citrate
Moderate-level interactions include other anticholinergic or antimuscarinic agents (e.g. atropine, hyoscyamine, dicyclomine, glycopyrronium, propantheline, clidinium, mepenzolate, methscopolamine), opioids and related agents (morphine, loperamide, opium, eluxadoline), and others such as metoclopramide, dronabinol, nabilone and pramlintide.
Conditions flagged for caution or contraindication in the compiled safety data include:
- Eye: angle-closure and open-angle glaucoma
- Gastrointestinal: paralytic ileus, achalasia, megaesophagus, ulcerative colitis, inflammatory bowel disease, Clostridium difficile colitis, necrotizing enterocolitis, gastric ulcer, hiatus hernia
- Genitourinary: benign prostatic hyperplasia, pyoureter
- Neuromuscular: myasthenia gravis, neuromuscular junction disease
- Cardiovascular: coronary artery disease, heart conduction disease, sudden cardiac arrest, hypertension, hypotension
- Other: chronic obstructive pulmonary disease, kidney disease, liver disease, gallbladder disease
These are not drawn from label text and should be checked against the PI.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for PLA2G6-associated neurodegeneration is supported only by a computational score (0.9917), with no clinical trials or publications directly studying this disease. Any benefit would likely be symptomatic at best, and anticholinergic adverse effects need careful weighing in a neurodegenerative population.
To proceed, the following is needed:
- Literature review and trial search focused on PLA2G6-associated neurodegeneration and anticholinergic treatment of its dystonia-parkinsonism features
- Detailed mechanism of action data for benzatropine
- Review of the TGA Product Information for warnings, contraindications and approved indications
- A safety assessment covering anticholinergic burden, cognitive effects and the interaction profile in this population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.